Skip to content

XORTX Therapeutics (XRTX) Stock Soared 129% on Clinical Trial

Simon Mugo trader
Updated 19 Jan 2023

The XORTX Therapeutics Inc (NASDAQ: XRTX) stock soared 128.8% after reporting positive topline data from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial to characterize the pharmacokinetics of its unique formulation of oral oxypurinol, XORLOTM.

new-recommended-broker-banner

YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Investors cheered the news as the results indicated that XORLOTM was well tolerated across the multiple dosing regimens. The study did not identify any safety issues in the 88 participants who received the drug within the four parts.

Top Broker Recommendation

YOUR CAPITAL IS AT RISK. 68% OF RETAIL CFD ACCOUNTS LOSE MONEY

The study results showed a substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform and allowed for an increased dose proportionality compared to non-formulated oxypurinol.

The trial further allowed for multiple dosing regimens that achieved therapeutic target values and confirmed the innovations claimed in the recently granted US and EU patents regarding XORTX’s unique proprietary formulations of oxypurinol.

The late-stage clinical pharmaceutical company said that the trial results would enable precise dosing recommendations for the upcoming late-stage Phase 3 registration trial in patients with progressing kidney disease caused by autosomal dominant polycystic kidney disease (ADPKD).

ADPKD is a rare disease that affects over 10 million individuals globally. ADPKD is typically diagnosed based on the expansion of fluid-filled cysts in the kidneys. Over time, the increasing number and size of cysts can contribute to structural and functional changes in kidneys and are frequently accompanied by chronic pain, a common problem for patients with ADPKD. 

Current treatments for ADPKD include dietary restrictions and anti-hypertensive drugs. New therapies that can effectively slow kidney function decline in ADPKD are needed.

Dr Allen Davidoff, the XORTX Therapeutics CEO, stated: “We are pleased to have achieved this important milestone in the development of XORLOTM, the Company’s proprietary oral formulation of oxypurinol. The comprehensive characterization of this drug and its unique proprietary formulation provides a substantial understanding of how the XORLOTM formulation behaves pharmacokinetically in individuals. Importantly, the compiled data set from the four parts of this Study demonstrates an innovative and substantial improvement on the drug product that can now be used to guide the development of population pharmacokinetic models to inform dosing in individuals with ADPKD in our upcoming late-stage Phase 3 registration trial.”

*This is not investment advice.

XORTX Therapeutics (XRTX) stock price. 

The XORTX Therapeutics (XRTX) stock soared 128.81% to trade at $1.7911, from Wednesday’s closing price of $0.7828.


YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading